Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Menopausal women who take a certain type of soy supplement long-term aren't at increased risk for breast cancer or any other ill effects, a new two-year study suggests.
The PAL Trial, announced at the 2010 San Antonio Breast Cancer Symposium, showed that women whose lymph nodes are removed during breast cancer surgery may safely lift weights of 1 to 2 pounds without increasing their chances for developing lymphedema.
Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.
The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.
Members of Living Beyond Breast Cancer's Medical Advisory Board react to the FDA decision to withdraw approval of Avastin as a treatment for metastatic breast cancer.
Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.
FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.
NEW YORK (Reuters Health) - A diagnosis of breast cancer will inevitably sink a woman's mood, but those whose spirits lift over time appear to survive longer, a new study suggests.
NEW YORK (Reuters Health) - A new radiation treatment for breast cancer is becoming increasingly popular despite lack of good evidence, at least among well-insured Medicare patients, U.S. researchers say,.
NEW YORK (Reuters) - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.